These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12123337)

  • 1. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer.
    Hamilton A; Biganzoli L; Coleman R; Mauriac L; Hennebert P; Awada A; Nooij M; Beex L; Piccart M; Van Hoorebeeck I; Bruning P; de Valeriola D
    Ann Oncol; 2002 Jun; 13(6):910-8. PubMed ID: 12123337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
    Lyass O; Uziely B; Ben-Yosef R; Tzemach D; Heshing NI; Lotem M; Brufman G; Gabizon A
    Cancer; 2000 Sep; 89(5):1037-47. PubMed ID: 10964334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of Doxil and vinorelbine in metastatic breast cancer.
    Burstein HJ; Ramirez MJ; Petros WP; Clarke KD; Warmuth MA; Marcom PK; Matulonis UA; Parker LM; Harris LN; Winer EP
    Ann Oncol; 1999 Sep; 10(9):1113-6. PubMed ID: 10572612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer.
    Caponigro F; Comella P; Budillon A; Bryce J; Avallone A; De Rosa V; Ionna F; Comella G
    Ann Oncol; 2000 Mar; 11(3):339-42. PubMed ID: 10811502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
    Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
    Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
    Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
    Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group.
    Gogas H; Papadimitriou C; Kalofonos HP; Bafaloukos D; Fountzilas G; Tsavdaridis D; Anagnostopoulos A; Onyenadum A; Papakostas P; Economopoulos T; Christodoulou C; Kosmidis P; Markopoulos C
    Ann Oncol; 2002 Nov; 13(11):1737-42. PubMed ID: 12419745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
    Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.
    Holmes FA; Valero V; Walters RS; Theriault RL; Booser DJ; Gibbs H; Fraschini G; Buzdar AU; Willey J; Frye D; Asmar L; Hortobagyi GN
    Ann Oncol; 1999 Apr; 10(4):403-11. PubMed ID: 10370782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience.
    Perez AT; Domenech GH; Frankel C; Vogel CL
    Cancer Invest; 2002; 20 Suppl 2():22-9. PubMed ID: 12442346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor.
    Pavlick AC; Chodkiewicz C; Liebes L; Hamilton A; Wasserheit C; Hochster H; Speyer J; Phillips Z; Downey A; Sorich J; Muggia F
    Anticancer Drugs; 2004 Feb; 15(2):119-25. PubMed ID: 15075667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
    Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
    Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.
    Ranson MR; Carmichael J; O'Byrne K; Stewart S; Smith D; Howell A
    J Clin Oncol; 1997 Oct; 15(10):3185-91. PubMed ID: 9336354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.
    Gabizon AA
    Cancer Invest; 2001; 19(4):424-36. PubMed ID: 11405181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
    O'Brien ME; Wigler N; Inbar M; Rosso R; Grischke E; Santoro A; Catane R; Kieback DG; Tomczak P; Ackland SP; Orlandi F; Mellars L; Alland L; Tendler C;
    Ann Oncol; 2004 Mar; 15(3):440-9. PubMed ID: 14998846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
    Marina NM; Cochrane D; Harney E; Zomorodi K; Blaney S; Winick N; Bernstein M; Link MP
    Clin Cancer Res; 2002 Feb; 8(2):413-8. PubMed ID: 11839657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-escalating pilot study of sterically stabilized, pegylated liposomal doxorubicin (Lipo-Dox) in patients with metastatic breast cancer.
    Chao TC; Wang WS; Yen CC; Chiou TJ; Liu JH; Chen PM
    Cancer Invest; 2003; 21(6):837-47. PubMed ID: 14735687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.